WADA prohibited list raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-10. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
== Research == Moroder started his peptide research with the synthesis of the S-peptide of ribonuclease A and studies on this protein-peptide complex. It was one of the first demonstrations of the key and lock principle in peptide hormone receptor interactions. As research associate he worked on the synthesis of radioactive adrenocorticotropin, which represents one of the first synthetic research works on human peptide hormones. Moroder's work at the Max Planck Institute for Biochemistry in Martinsried was initially focused on the gastrin and cholecystokinin system, revealing the mechanism for the membrane-bound pathway of hormone recognition by the receptors. In parallel, he worked on synthetic methods in peptide and protein chemistry such as the introduction of di-tert-butyl dicarbonate as a general and widely used reagent in peptide chemistry, regioselective assembly of cystine-rich peptides, and the synthesis of highly robust disulfide and diselenide scaffolds. In the later phase of his research, Moroder became increasingly interested in the study of more complex biological and medical systems by chemical means. For example, he addressed fundamental questions of the kinetics of protein folding and actively contributed to the design and synthesis of enzyme inhibitors involved in various diseases, including cancer. In the 1990s Luis Moroder and Robert Huber supported Nediljko Budisa in establishing genetic code engineering in Germany - a research area that merges chemical syntheses with biological complexities in the form of chemical synthetic biology (Xenobiology).
The report concludes that the tactics of the Special Demonstration Squad were not justified, and that most groups infiltrated by its members posed no threat to national security. The report also finds that the SDS should have been disbanded early on. 30 June – Charlotte Dewar, chief executive of the Independent Press Standards Organisation, says the watchdog is considering the media coverage surrounding the death of Nicola Bulley, but has no current plans to launch an investigation.
In order to excite surface plasmon polaritons in a resonant manner, one can use electron bombardment or incident light beam (visible and infrared are typical). The incoming beam has to match its momentum to that of the plasmon. In the case of p-polarized light (polarization occurs parallel to the plane of incidence), this is possible by passing the light through a block of glass to increase the wavenumber (and the momentum), and achieve the resonance at a given wavelength and angle. S-polarized light (polarization occurs perpendicular to the plane of incidence) cannot excite electronic surface plasmons. Electronic and magnetic surface plasmons obey the following dispersion relation:
10 October – The Scottish Government shelves plans for the early release of long term prisoners following concerns raised by victims groups, but will reduce the automatic early release for short term prisoners from the point of 50% completion of their sentence to 40%. 11 October – It is reported that Education Secretary Jenny Gilruth has withheld £145.5m in funding to all councils because of a disagreement over cuts to the number of teachers. 12 October – Alex Salmond, former first minister of Scotland, dies aged 69 in North Macedonia. 13 October – Flags are lowered to half-mast at the Scottish Parliament following the death of former First Minister Alex Salmond the previous day. MSP John Mason is expelled from the SNP after posting on Twitter that there was "no genocide" in Gaza. 14 October – The Scottish Government confirms that ferry fares in Scotland will increase by 10% from 1 January 2025. Glasgow City Council unveils plans to make improvements to the city centre, with the changes scheduled to begin in 2025. 16 October – Following trial and conviction at the High Court in Edinburgh, Jamie Boulton is sentenced to life imprisonment with at least 18 years in custody for the stabbing murder of Gary O'Neill at a flat in Leith in June 2023. 17 October – BBC One programme Crimewatch Live makes a fresh appeal for information leading to the discovery of the remains of Suzanne Pilley, who was murdered by her ex-partner in 2010.
Sources: en.wikipedia.org
== Medical uses == An intravenous infusion of oxytocin is used to induce labor and to support labor in case of slow childbirth if the oxytocin challenge test fails. The physiology of labor stimulated by oxytocin administration is similar to the physiology of spontaneous labor. It is associated with less tachysystole (more than five contractions in 10 minutes, averaged over a 30-minute period, which can but does not always cause fetal distress) than other induction methods and allows achievement of delivery with amniotomy to proceed faster. Whether a high dose is better than a standard dose for labor induction is unclear. It has largely replaced ergometrine as the principal agent to increase uterine tone in acute postpartum hemorrhage. Oxytocin is also used in veterinary medicine to facilitate birth and to stimulate milk release. The tocolytic agent atosiban (Tractocile) acts as an antagonist of oxytocin receptors. It is registered in many countries for use in suppressing premature labor between 24 and 33 weeks of gestation. It has fewer side effects than drugs previously used for this purpose (such as ritodrine, salbutamol and terbutaline). Oxytocin has not been found to be useful for improving breastfeeding success.
==== Reactive oxygen species ==== α-Ketoglutarate is one of the non-enzymatic antioxidant agents. It reacts with hydrogen peroxide (H2O2) to form succinate, carbon dioxide (i.e., CO2), and water (i.e., (H2O) thereby lowering the levels of H2O2. Additionally, α-ketoglutarate increases the activity of superoxide dismutase, which converts the highly toxic (O−2) radical to molecular oxygen (i.e., O2) and H2O2.
People in ancient East Asia ate tea for centuries, perhaps even millennia, before ever consuming it as a beverage. They would nibble on the leaves raw, add them to soups or greens, or ferment them and chew them as areca nut is chewed. Tea drinking may have begun in the region of Yunnan, where it was used for medicinal purposes. It is believed that in Sichuan, "people began to boil tea leaves for consumption into a concentrated liquid without the addition of other leaves or herbs, thereby using tea as a bitter yet stimulating drink, rather than as a medicinal concoction." Chinese legends attribute the invention of tea to the mythical Shennong (in central and northern China) in 2737 BC, although evidence suggests that tea drinking may have been introduced from southwest China. The earliest written records of tea come from China. The word tú 荼 appears in the Shijing and other ancient texts to signify a kind of "bitter vegetable" (苦菜), and it is possible that it referred to many different plants such as sow thistle, chicory, or smartweed, as well as tea. In the Chronicles of Huayang, it was recorded that the Ba people in Sichuan presented tu to the Zhou king. The Qin later conquered the state of Ba and its neighbour Shu, and according to the 17th-century scholar Gu Yanwu who wrote in Ri Zhi Lu (日知錄): "It was after the Qin had taken Shu that they learned how to drink tea." Another possible early reference to tea is found in a letter written by the Qin dynasty general Liu Kun who requested that some "real tea" to be sent to him.
Sources: en.wikipedia.org
=== Male breasts === Both females and males develop breasts from the same embryological tissues. Anatomically, male breasts do not normally contain lobules and acini that are present in females. In rare instances, it is possible for very few lobules to be present; this makes it possible for some men to develop lobular carcinoma of the breast. Normally, males produce lower levels of estrogens and higher levels of androgens, namely testosterone, which suppress the effects of estrogens in developing excessive breast tissue. In boys and men, abnormal breast development is manifested as gynecomastia, the consequence of a biochemical imbalance between the normal levels of estrogen and testosterone in the male body. Around 70% of boys temporarily develop breast tissue during adolescence. The condition usually resolves by itself within two years. When male lactation occurs, it is considered a symptom of a disorder of the pituitary gland.
Carbon dioxide is gaining popularity among coffee manufacturers looking to move away from classic decaffeinating solvents. sCO2 is forced through green coffee beans which are then sprayed with water at high pressure to remove the caffeine. The caffeine can then be isolated for resale (e.g., to pharmaceutical or beverage manufacturers) by passing the water through activated charcoal filters or by distillation, crystallization or reverse osmosis. Supercritical carbon dioxide is used to remove organochloride pesticides and metals from agricultural crops without adulterating the desired constituents from plant matter in the herbal supplement industry. Supercritical carbon dioxide can be used as a solvent in dry cleaning. Supercritical carbon dioxide is used as the extraction solvent for creation of essential oils and other herbal distillates. Its main advantages over solvents such as hexane and acetone in this process are that it is non-flammable and does not leave toxic residue. Furthermore, separation of the reaction components from the starting material is much simpler than with traditional organic solvents. The CO2 can evaporate into the air or be recycled by condensation into a recovery vessel. Its advantage over steam distillation is that it operates at a lower temperature, which can separate the plant waxes from the oils. In laboratories, sCO2 is used as an extraction solvent, for example for determining total recoverable hydrocarbons from soils, sediments, fly-ash, and other media, and determination of polycyclic aromatic hydrocarbons in soil and solid wastes.
== Drug nomenclature for radiopharmaceuticals == As with other pharmaceutical drugs, there is standardization of the drug nomenclature for radiopharmaceuticals, although various standards coexist. The International Nonproprietary Name (INN) gives the base drug name, followed by the radioisotope (as mass number, no space, element symbol) in parentheses with no superscript, followed by the ligand (if any). It is common to see square brackets and superscript superimposed onto the INN name, because chemical nomenclature (such as IUPAC nomenclature) uses those. The United States Pharmacopeia (USP) name gives the base drug name, followed by the radioisotope (as element symbol, space, mass number) with no parentheses, no hyphen, and no superscript, followed by the ligand (if any). The USP style is not the INN style, despite their being described as one and the same in some publications (e.g., AMA, whose style for radiopharmaceuticals matches the USP style). The United States Pharmacopeial Convention is a sponsor organization of the USAN Council, and the USAN for a given drug is often the same as the USP name.
The Annals of Clinical & Laboratory Science is a quarterly academic journal. It is the official journal of, and is published by, the Association of Clinical Scientists. It was established in 1971 as Annals of Clinical Laboratory Science by F. William Sunderman and obtained its current title in 1973. As of 2022, the editor-in-chief is Nina Tatevian.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.